Citi Pharma
Citi Pharma Limited is a Lahore-based, Pakistan-listed pharmaceutical manufacturer producing 45+ APIs, finished formulations, and nutraceuticals for domestic and export markets across Uzbekistan, USA, UAE, Iraq, and Indonesia.
- Company typePublic
- Founded1992
- HeadquartersLahore, Pakistan
- Headcount1,001–5,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Citi Pharma does
Citi Pharma Limited is a Pakistan-based pharmaceutical company founded in 1992 and headquartered in Lahore, operating as a publicly listed entity on the Pakistan Stock Exchange with offices in Lahore and Karachi and a manufacturing facility in Bhai Pheru, District Kasur. The company operates a three-segment product portfolio: 45+ Active Pharmaceutical Ingredients (APIs) spanning analgesics, NSAIDs, antibiotics, anti-malarials, anti-diabetics, corticosteroids, and other therapeutic categories; finished dosage formulations in tablet, capsule, suspension, injection, and sachet forms under branded labels such as ASKPROL, CINGOL, PROMY, FOLAMIN, FLOXCIP, LENON, Cefask, and Triaxonecit; and a nutraceuticals line including vitamins, minerals, herbal supplements, and combination products under sub-brands like Vitamina-Z, Vitolux, Cidoxon, Redcal, Selvit, and CitIvy Syrup. Underpinning the portfolio is a claimed 25,000 sq/ft state-of-the-art R&D laboratory focused on nutraceutical molecule research, local reference standard development, and novel drug delivery systems.
The business model centers on direct B2B sales of APIs and formulations, complemented by a growing B2C nutraceuticals consumer line, with revenue generated through hardware/product sales rather than subscription or platform models. Distribution relies on direct export relationships (Uzbekistan for Ibuprofen, USA for Nutraceuticals, Dubai for Paracetamol and Amoxicillin) and international joint ventures targeting MENA and Southeast Asian markets. Pricing is not publicly disclosed. Go-to-market combines a sales-led motion with content marketing, LinkedIn presence, and conference participation (Health Expo Iraq, ISPE Singapore 2025). The company recently received SECP approval for a wholly owned REIT management subsidiary (CITI REIT Management Company Limited) marking diversification into real estate, and has initiated strategic partnerships in biotech and with the Gates Foundation to broaden its institutional footprint.
Citi Pharma firmographics
Firmographics- Name
- Citi Pharma
- Legal name
- Citi Pharma Limited
- Website
- https://www.citipharma.com.pk
- Company type
- Public
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Citi Pharma Limited is a Lahore-based, Pakistan-listed pharmaceutical manufacturer producing 45+ APIs, finished formulations, and nutraceuticals for domestic and export markets across Uzbekistan, USA, UAE, Iraq, and Indonesia.
- Ownership category
- akta.pro rank
Citi Pharma industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Multivitamins & Daily Packs (CRADAGAC)
Keywords
Where Citi Pharma is headquartered
LocationHeadquarters
- HQ city
- Lahore
- HQ country
- Pakistan
- HQ region
- Asia
Offices3 records
Markets served
Citi Pharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Products: Citi Pharma generates revenue through the manufacture and sale of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and nutraceutical products. The company exports to Uzbekistan (Ibuprofen), USA (Nutraceuticals), and Dubai (Paracetamol and Amoxicillin).
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Citi Pharma product offering
Product offeringCore offering
Citi Pharma manufactures and sells Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations (capsules, tablets, syrup drops, ointments, sachets), and nutraceutical products under its Citi Natural sub-brand. The company runs a 25,000 sq/ft state-of-the-art R&D laboratory that supports drug delivery research and reference-standard development. It supplies both domestic Pakistani markets and export markets in Uzbekistan, the USA, the UAE (Dubai), Iraq, and Indonesia.
Product overview
Citi Pharma is a Pakistani pharmaceutical company offering a three-segment product portfolio: (1) Active Pharmaceutical Ingredients (API) encompassing 45+ molecules across analgesics, NSAIDs, antibiotics (quinolones, penicillins, cephalosporins, macrolides), anti-malarials, anti-diabetics, and other therapeutic categories; (2) Finished Dosage Formulations including branded medications like ASKPROL (analgesics), CINGOL (respiratory), Cefask/Triaxonecit (antibiotics), and others in tablet, capsule, suspension, and injection forms; and (3) Nutraceuticals including vitamins, minerals, herbal supplements in tablet, capsule, syrup, and sachet formats. The company operates a 25,000 sq/ft R&D laboratory for new molecule research and drug delivery innovation.
Differentiator
Problem solved
Functional benefit
Brands
- Citi Natural: A product sub-brand mentioned under the products section.
Products and services
- Active Pharmaceutical Ingredients (APIs) Manufactured active pharmaceutical ingredients supplied primarily to other pharmaceutical manufacturers as raw input materials for their own formulations. APIs are produced at the company's facilities in Pakistan and supported by in-house reference-standard development capability.
- Pharmaceutical Formulations Finished pharmaceutical formulations in multiple dosage forms including capsules, tablets, syrups, drops, ointments, and sachets. Branded product families include ASKPROL (analgesic line with ASKPROL EXTRA, ASKPROL-M MIGRAINE, ASKPROL TABLET, ASKPROL Suspension variants), CINGOL (respiratory), PROMY (Omeprazole), FOLAMIN (nutritional), FLOXCIP, LENON, Cefask, and Triaxonecit (antibiotics). Sold domestically in Pakistan and exported to international markets including Uzbekistan, USA, UAE (Dubai), Iraq, and Indonesia.
- Citi Natural Nutraceuticals Nutraceutical / dietary supplement product line marketed under the Citi Natural sub-brand. Sub-products include Vitamina-Z Tablet, Vitolux Tablet, Cidoxon Tablet, Redcal Tablet, Selvit Capsule, and CitIvy Syrup. Targeted at consumers seeking vitamins, minerals, and nutritional support products sold through retail and pharmacy channels.
Companies that use Citi Pharma
Customer profileSegments2 records
Ideal customer profiles2 records
Citi Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Citi Pharma partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Gates FoundationcoreCiti Pharma hosted a productive meeting with the Gates Foundation team to explore opportunities for collaboration on innovative healthcare solutions. The company aims to drive meaningful impact in global health through this potential partnership.
- ISPE (International Society for Pharmaceutical Engineering)minorMD Dr Zamir Ul Hussan connected with global pharma leaders at ISPE Singapore 2025, exchanging insights on innovation, quality, and the future of healthcare.
- Strategic Biotech PartnercoreStrategic partnership bringing advanced biotech technologies, promoting local research, and creating high-value jobs. The partnership strengthens local manufacturing, reduces import reliance, and boosts export potential.
- International Joint Ventures PartnerscoreInternational joint ventures for API expansion, establishment of pharmaceutical manufacturing facilities, and expansion into MENA region. Includes collaboration with Ambassador of Indonesia at Citi Pharma Plant.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Citi Pharma competitors and assessment
Company assessmentDirect peers
- The Searle Company: Pakistani publicly listed pharma manufacturer with diversified branded generics, APIs, and nutraceutical/nutrition portfolio, operating internationally with similar product segmentation to Citi Pharma.
- Hilton Pharma: Karachi-based pharmaceutical company manufacturing branded generics, APIs, and over-the-counter products with strong domestic distribution and select export reach, closely matching Citi Pharma's domestic-plus-export model.
- Ferozsons Laboratories: Listed Pakistani pharma company with branded generics, API manufacturing, and a partnership with Gilead for hepatitis C treatment; comparable as a manufacturer with API capabilities and international collaborations.
- Barrett Hodgson Pakistan: Pakistan's leading sterile injectable manufacturer with API and formulation capabilities, including beta-lactam antibiotics — directly overlapping Citi Pharma's Triaxonecit (Ceftriaxone) and cephalosporin product lines.
- Getz Pharma: Pakistan's largest pharmaceutical manufacturer producing APIs, formulations, and branded generics across antibiotics, cardiovascular, and nutraceuticals; directly comparable as a domestic pharma with manufacturing, exports, and 1,000+ employee scale.
- Highnoon Laboratories: Pakistan-based pharma manufacturer producing APIs, finished formulations, and specialty products across antibiotics, anti-malarials, and cardiovascular; comparable in API-plus-formulation vertical integration and headcount scale.
- AGP Limited: Pakistan-based pharmaceutical manufacturer producing branded generics and OTC products across cardiovascular, gastrointestinal, and nutraceutical segments, similar in size and therapeutic breadth to Citi Pharma.
- Sami Pharmaceuticals: Karachi-headquartered pharma manufacturer with branded generics, specialty products, and exports; comparable in therapeutic portfolio and regional export orientation.
Broad incumbents
- Aurobindo Pharma: Large Indian generic and API manufacturer with extensive global presence across antibiotics, anti-retrovirals, and nutraceuticals; sets the competitive benchmark for cost-efficient API-plus-formulation players seeking regulated market exports.
- Cipla: India-headquartered global pharmaceutical major with APIs, formulations, and nutraceuticals across 80+ countries; serves as a comparable incumbent in the broader generics and API space where Citi Pharma competes for export markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Citi Pharma social profiles
Digital presenceCiti Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Citi Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Citi Pharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Citi Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Citi Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Citi Pharma
What does Citi Pharma do?
Citi Pharma manufactures and sells Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations (capsules, tablets, syrup drops, ointments, sachets), and nutraceutical products under its Citi Natural sub-brand. The company runs a 25,000 sq/ft state-of-the-art R&D laboratory that supports drug delivery research and reference-standard development. It supplies both domestic Pakistani markets and export markets in Uzbekistan, the USA, the UAE (Dubai), Iraq, and Indonesia.
Is Citi Pharma a public or private company?
Citi Pharma is a public company. It is classified as public and is currently operating.
When was Citi Pharma founded?
Citi Pharma was founded in 1992. It employs 1,001 to 5,000 people.
Where is Citi Pharma based?
Citi Pharma is headquartered in Lahore, Pakistan, in the Asia region.
How does Citi Pharma make money?
One revenue line is on record: pharmaceutical Products.
Who are Citi Pharma's main competitors?
Direct peers on record are The Searle Company, Hilton Pharma, Ferozsons Laboratories, Barrett Hodgson Pakistan, Getz Pharma, Highnoon Laboratories, AGP Limited and Sami Pharmaceuticals. Broad incumbents are Aurobindo Pharma and Cipla.
Does Citi Pharma have an API?
No public API is recorded for Citi Pharma.
What industry is Citi Pharma in?
Citi Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is CRADAGAC, Multivitamins & Daily Packs. Its NAICS code is 325412 and its SIC code is 2834.